Alternatives to antibiotics
- 1.6k Downloads
Infection remains one of the main reasons for admission to intensive care units (ICU). As a consequence, more than 60 % of ICU patients receive antibiotics during their stay in the ICU , despite implementation of antibiotic stewardship programs to improve the quality of antibiotic use [2, 3]. In most countries antibiotic consumption is mainly driven by pulmonary infections, such as community acquired pneumonia (CAP), healthcare associated pneumonia (HCAP), hospital acquired pneumonia (HAP), and ventilator associated pneumonia (VAP). Bacterial resistance has concurrently increased, especially for Gram negative bacilli, including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii, while prevalence of methicillin resistance among Staphylococcus aureus has remained stable or declined in most European countries . Yet, very few new antibiotics have been developed over the past decade and only a few novel drugs are in the development pipeline of pharmaceutical...
KeywordsIntensive Care Unit Intensive Care Unit Patient Ventilator Associate Pneumonia Acinetobacter Baumannii Intensive Care Unit Setting
Compliance with ethical standards
Conflicts of interest
Bruno Francois is the coordinating principal investigator of an ongoing international phase II trial testing a monoclonal antibody against S. aureus to prevent VAP in ICU patients in collaboration with Medimmune, a member of the AstraZeneca group. No other conflict of interest related to this manuscript to declare. Hasan Jafri is an employee of MedImmune, AstraZeneca, the manufacturer of anti-infectious disease monoclonal antibodies. He is currently leading the development and conduct of studies focused on prevention of nosocomial pneumonia, using monoclonal antibodies targeting S. aureus and P. aeruginosa. No other conflict of interest related to this manuscript to declare. Marc Bonten is a member of the study team of an ongoing international phase II trial testing a monoclonal antibody against S. aureus to prevent VAP in ICU patients in collaboration with Medimmune, a member of the AstraZeneca group, as part of the IMI-funded COMBACTE and COMBACTE MAGNET projects. No other conflict of interest related to this manuscript to declare.
- 3.Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society (2012) Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33:322–327CrossRefGoogle Scholar
- 4.European Centre for Disease Prevention and Control (2015) Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections. ECDC, Stockholm. http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf. Accessed 11 Feb 2016
- 6.Timsit JF, Perner A, Bakker J, Bassetti M, Benoit D, Cecconi M et al (2015) Year in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics. Intensive Care Med 41(4):575–588CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Que Y, Lazar H, Wolff M, Francois B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P (2014) Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis 33(10):1861–1867CrossRefPubMedGoogle Scholar
- 9.Francois B, Luyt CE, Dugard A, Wolff M, Diehl J, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J (2012) Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 40(8):2320–2326CrossRefPubMedGoogle Scholar
- 10.DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK (2014) A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6(262):262ra155CrossRefPubMedGoogle Scholar
- 15.Shaw KJ, Lehman SM, Smrekar F, Weiss WJ, Pulse M, Morales SP (2015) Efficacy of a bacteriophage cocktail in a Staphylococcus aureus mouse pneumonia model is comparable to vancomycin. Poster presentation, ICAAC/ICC 2015, San DiegoGoogle Scholar
- 17.Sahota JS, Smith CM, Radhakrishnan P, Winstanley C, Goderdzishvili M, Chanishvili N, Kadioglu A, O’Callaghan C, Clokie MR (2015) Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv 28(5):353–360CrossRefPubMedGoogle Scholar